Design, synthesis and in vitro antiproliferative activity of new thiazolidinedione-1,3,4-oxadiazole hybrids as thymidylate synthase inhibitors

References

• Goud NS, Ghouse SM, Arifuddin M, et al. Synthesis and biological evaluation of coumarin-1,3,4-oxadiazole hybrids as selective carbonic anhydrase IX and XII inhibitors. Bioorg Chem 2019;87:765–72.
   PubMed Web of Science ®Google Scholar
• Patel K, Karthikeyan C, Solomon VR, et al. Synthesis of some coumarinyl chalcones and their antiproliferative activity against breast cancer cell lines. Lett Drug Design Disc 2011;8:308–11.
   Web of Science ®Google Scholar
• Lambratu R, Donna V, Monzur R, et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 2004;5:341–51.
   PubMed Web of Science ®Google Scholar
• Young DW. Studies on thymidylate synthase and dihydrofolate reductase-two enzymes involved in the synthesis of thymidine. Chem Soc Rev 1994; 23:119–28.
   Web of Science ®Google Scholar
• Kumar VP, Cisneros JA, Frey KM, et al. Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase. Bioorg Med Chem Lett 2014;24:4158–61.
   PubMed Web of Science ®Google Scholar
• Catalano A, Luciani R, Carocci A, et al. X-ray crystal structures of Enterococcus faecalis thymidylate synthase with folate binding site inhibitors. Eur J Med Chem 2016;123:649–64.
   PubMed Web of Science ®Google Scholar
• Onen FE, Boum Y, Jacquement C, et al. Design, synthesis and evaluation of potent thymidylate synthase X inhibitors. Bioorg Med Chem Lett 2008;18:3628–31.
   PubMedGoogle Scholar
• Friedkin M, Kornberg A. The enzymatic conversion of deoxyuridylic acid to thymidylic acid and the participation of tetrahydrofolic acid. In: Mc Elroy WD and Glass B, eds. The Chemical Basis of Heredity. Baltimore: Johns Hopkins Press; 1957:609–614.
   Google Scholar
• Navalgund LG, Rossana C, Muench AJ, et al. Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem 1980;255:7386–90.
   PubMed Web of Science ®Google Scholar
• Nazreen S, Alam MS, Hamid H, et al. Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists. Eur J Med Chem 2014;87:175–85.
   PubMed Web of Science ®Google Scholar
• Unlusoy MC, Verspohl EJ, Ertan R. Synthesis and antidiabetic activity of some new chromonyl-2,4-thiazolidinediones. J EzyInhib Med Chem 2010; 25:784–9.
   Web of Science ®Google Scholar
• Chen R, Yan J, Liu P, et al. Effects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: a meta-analysis of randomized controlled trials. PLoS ONE 2015;10:e0123703.
   PubMedGoogle Scholar
• Hu CF, Zhang PL, Sui YF, et al. Ethylenic conjugated coumarin thiazolidinediones as new efficient antimicrobial modulators against clinical methicillin-resistant Staphylococcus aureus. Bioorg Chem 2020; 94:103434.
   PubMed Web of Science ®Google Scholar
• Shankar S, Vuppu S. In vitro drug metabolism and pharmacokinetics of a novel thiazolidinedione derivative, a potential anticancer compound. J Pharma Biomed Anal 2020;179:113000.
   PubMed Web of Science ®Google Scholar
• Tokala R, Thatikonda S, Sana S, et al. Synthesis and in vitro cytotoxicity evaluation of β-carboline-linked 2,4-thiazolidinedione hybrids: potential DNA intercalation and apoptosis-inducing studies. New J Chem 2018;42:16226–36.
   Web of Science ®Google Scholar
• Trotsko N, Przekora A, Zalewska Z, et al. Synthesis and in vitro antiproliferative and antibacterial activity of new thiazolidine-2,4-dione derivatives. J EzyInhib Med Chem 2018;33:17–24.
   Web of Science ®Google Scholar
• Shimazaki N, Togashi N, Hanai M, et al. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur J Cancer 2008;44:1734–43.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Copland JA, Brose MS, et al. Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrin Metab 2013;98:2392–400.
   PubMed Web of Science ®Google Scholar
• Belfiore A, Genua M, Malaguarnera R. PPAR-γ agonists and their effects on IGF-i receptor signaling: implications for cancer. PPAR Res 2009;2009:1–18.
   Web of Science ®Google Scholar
• Lee WH, Kim SG. AMPK-dependent metabolic regulation by PPAR agonists. PPAR Res 2010;2010:1–10.
   Web of Science ®Google Scholar
• Knight SD, Adams ND, Burgess JL, et al. Discovery of GSK2126458, a highly potent inhibitor of pi3k and the mammalian target of rapamycin. Med Chem Lett 2010;1:39–43.
   PubMed Web of Science ®Google Scholar
• Liu K, Rao W, Parikh H, et al. 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization. Eur J Med Chem 2012;47:125–36.
   PubMed Web of Science ®Google Scholar
• James ND, Growcott JW. Zibotentan. Drugs Future 2009;34:624–33.
   Web of Science ®Google Scholar
• Shen W, Xi H, Li C, et al. Endothelin‐A receptor in gastric cancer and enhanced antitumor activity of trastuzumab in combination with the endothelin—A receptor antagonist ZD4054. Ann N Y Acad Sci 2019;1448:30–41.
   PubMed Web of Science ®Google Scholar
• Du QR, Li DD, Pi YZ, et al. Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents. Bioorg Med Chem 2013;21:2286–97.
   PubMed Web of Science ®Google Scholar
• Abbot V, Sharma P, Dhiman S, et al. Small hybrid heteroaromatics: resourceful biological tools in cancer research. RSC Adv 2017;7:28313–49.
   Web of Science ®Google Scholar
• WahbaAJ FM. The enzymatic synthesis of thymidylate: i. early steps in the purification of thymidylate synthetase of Escherichia coli. JBiol Chem 1962;237:3794.
   PubMed Web of Science ®Google Scholar
• Davisson VJ, Sirawaraporn W, Santi DV. Expression of human thymidylate synthase in Escherichia coli. J Biol Chem 1989;264:9145–8.
   PubMed Web of Science ®Google Scholar
• Morris GM, Goodsell GS, Halliday RS, et al. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639–62.
   Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 2001;46:3–26.
   PubMed Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615–23.
   PubMed Web of Science ®Google Scholar
• Patrick AH, Jonathan BC, John OT. Molecular docking of intercalators and groove- binders to nucleic acids using autodock and surflex. J Chem Inf Model 2008;48:1602–15.
   PubMed Web of Science ®Google Scholar
• Oleg T, Arthur JO. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 2010;31:455–61.
   PubMed Web of Science ®Google Scholar
• Lamia HTA, Taghreed ZS, Abeer MN. Design, synthesis, anticancer evaluation and docking studies of new pyrimidine derivatives as potent thymidylate synthase inhibitors. Bioorg Chem 2019;91:103159.
   PubMed Web of Science ®Google Scholar
• Ahmed FE, Qasem MAA, Emad S. Design, synthesis, molecular docking of new thiopyrimidine-5-carbonitrile derivatives and their cytotoxic activity against HepG2 cell line. J Appl Pharm Sci 2014;4:102–11.
   Google Scholar